Regular rituximab treatment lessens NMOSD relapses: Real-world data
Regular maintenance treatment with low-dose rituximab is associated with less disability and fewer relapses among people with neuromyelitis optica spectrum disorder (NMOSD) compared with receiving irregular doses of the preventive therapy, according to a two-year real-world study in China. “Regular [rituximab] treatment can significantly reduce the annual relapse rate, incidence…